Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

NIH 4OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Esophageal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 262Specimen Handling 253pembrolizumab 230Cyclophosphamide 216Radiotherapy 204Nivolumab 168Cisplatin 161Carboplatin 145Biopsy 144Radiosurgery 128fludarabine 123Blood Specimen Collection 116Gemcitabine 111Paclitaxel 107Surveys and Questionnaires 106Standard of Care 102venetoclax 94Dexamethasone 93Bevacizumab 92Radiation 87Rituximab 81Capecitabine 80Cytarabine 79Oxaliplatin 77Drug Therapy 75Doxorubicin 75Ipilimumab 73durvalumab 70fludarabine phosphate 69atezolizumab 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × CA-4948 × 90 days × Clear all
NCT05187182 2026-04-27

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Washington University School of Medicine

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT07107750 2026-04-03

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Washington University School of Medicine

Phase 1 Recruiting
48 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡